Rossari Biotech delivers strong performance in Q2FY2022 triggered by uptick in all the segment & recent acquisitions | Q2 FY22 4 Point Result Analysis & Earning Call
Rossari Biotech delivers strong performance in Q2FY2022 triggered by uptick in all the segment & recent acquisitions | Q2 FY22 4 Point Result Analysis & Earning Call
Rossari Biotech delivers strong performance in Q2FY2022 triggered by uptick in all the segment & recent acquisitions | Q2 FY22 4 Point Result Analysis & Earning Call
Published on 12 November 2021 .Views 23.Comments 0
Share On
The company has delivered strong topline & bottom line growth aided by strong growth momentum across all segments as well as recent acquisitions. But Margins tumbled due to extremely heavy inflationary pressure across segments
Download
